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Extramedullary disease is relatively frequent in multiple myeloma, but ourknowledge on the subject is limited and mainly relies on small case series orsingle center experiences. Little is known regarding the role of new drugs in
this setting. We performed a meta-analysis of eight trials focused on the descrip-
tion of extramedullary disease characteristics, clinical outcome, and response to
new drugs. A total of 2,332 newly diagnosed myeloma patients have been includ-
ed; 267 (11.4%) had extramedullary disease, defined as paraosseous in 243
(10.4%), extramedullary plasmocytoma in 12 (0.5%), and not classified in 12
(0.5%) patients. Median progression-free survival was 25.3 months and 25.2 in
extramedullary disease and non-extramedullary disease patients, respectively.  In
multivariate analysis the presence of extramedullary disease did not impact on
progression-free survival (hazard ratio 1.15, P=0.06), while other known prognos-
tic factors retained their significance. Patients treated with immunomodulatory
drugs, mainly lenalidomide, or proteasome inhibitors had similar progression-free
survival and progression-free survival-2 regardless of extramedullary disease pres-
ence. Median overall survival was 63.5 months and 79.9 months (P=0.01) in
extramedullary and non-extramedullary disease patients, respectively, and in mul-
tivariate analysis the presence of extramedullary disease was associated with a
reduced overall survival (hazard ratio 1.41, P<0.001), in line with other prognostic
factors. With the limits of the use of low sensitivity imaging techniques, that lead
to an underestimation of extramedullary disease, we conclude that in patients
treated with new drugs the detrimental effect of extramedullary disease at diag-
nosis is limited, that lenalidomide is effective as are proteasome inhibitors, and
that these patients tend to acquire a more aggressive disease in later stages.
(EUDRACT2005-004714-32, NCT01063179. NCT00551928, NCT01091831,
NCT01093196, NCT01190787, NCT01346787, NCT01857115).
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ABSTRACT
Introduction
Multiple myeloma (MM) is a plasma cell neoplasia char-
acterized by a diffuse tumor infiltration of the bone mar-
row, resulting, among others, in anemia, bone damage
with hypercalcemia, and bone lesions. Occasionally,  neo-
plastic plasma cells acquire a different growth pattern gen-
erating tumor masses, that are referred to as extra-
medullary disease (EMD).1 EMD can arise from skeletal
focal lesions, which disrupt the cortical bone and grow as
extra-bone masses, and is referred to as paraosseous plas-
mocytoma (PO), or derive from hematogenous spread as
manifestation in soft tissues, and is called extramedullary
plasmocytomas (EMP).  Incidence of EMD at diagnosis
ranges between 6% and 10%,2-4 while later in the course
of the disease this increases to 13%-26%,2,4 with a 32-35%
peak in case of relapse after allogeneic stem cell transplan-
tation.5,6 In the final stage of the disease, an extraskeletal
involvement is observed in approximately 70% of cases
studied with autopsy,7 with a peculiar involvement of vis-
ceral sites.8 As expected, patients with EMD at diagnosis
tend to maintain the same pattern at relapse.2 
The biological mechanisms behind the acquisition of
the EMD-forming phenotype have not yet been fully elu-
cidated. Increased expression of CXCR4 and CXCL12
plays a major role in promoting a bone marrow-indepen-
dent behavior, favoring dissemination, and homing to dis-
tant and unusual sites.9,10 Other mechanisms are represent-
ed by reduced expression of several adhesion molecules,
in particular VLA-4,  CD44, and CD56, and chemokine
receptors, such as CCR1, and CCR2. Diversely, the cyclin
D1 pathway seems to favor the bone marrow homing,
protecting from extramedullary localizations, as t(11;14) is
not observed in MM patients with EMD.11
Despite its frequency and clinical relevance, EMD has
often been neglected by the medical literature. In fact,
almost all the available data derive from retrospective
series and single center experiences, mainly reported  in
the pre-new drug era, with the limitations of this type of
studies. In order to fill this gap and clarify the role of new
drugs in MM with EMD, we conducted the largest  meta-
analysis so far reported, based on eight prospective trials
by the same sponsors (Fonesa Onlus and Hovon
Foundation). 
Methods
Study design
Patients with newly diagnosed MM enrolled in eight
clinical trials were retrospectively analyzed. Details on tri-
als and treatment regimens are summarized in Table 1.
Briefly, three trials enrolled transplant eligible and five tri-
als transplant ineligible patients. Three trials included an
immunomodulatory (IMiD) drug in the treatment,
lenalidomide in almost all cases, three trials a proteasome
inhibitor (PI), and four trials both. Six out of eight trials
included maintenance. Trials were approved by the
Independent Ethics Committees/Institutional Review
Boards at all participating centers. Patients provided writ-
ten informed consent before entering the study, prepared
in accordance with the Declaration of Helsinki. For the
purpose of this meta-analysis, we considered the sub-
group of patients with EMD, and compared them with
patients without EMD. 
Extramedullary disease definition and assessment
Extramedullary disease  was classified as PO disease,
consisting of tumor masses arising directly from bones, or
EMP, consisting of masses not contiguous to the bones
and derived from hematogenous spread. EMD was identi-
fied at study enrollment with the diagnostic procedure
required by the patient’s study protocol, such as X-ray
skeletal survey, magnetic resonance imaging (MRI), com-
puted tomography (CT), and physical examination.
Statistical analysis
Differences in patients' and disease characteristics for
EMD patients versus non-EMD patients were investigated
using Kruskal Wallis test for continuous variables and
Fisher’s exact test for categorical variables. Data of trials
were pooled together and analyzed. Time-to-event data
were analyzed using the Kaplan-Meier method; EMD and
non-EMD patients were compared with the log-rank test.
The Cox proportional hazards models were used to esti-
mate adjusted hazard ratios (HRs) and the 95% confi-
dence intervals (CI) for the main comparisons, EMD
patients versus non-EMD patients. To account for potential
confounders, the Cox models were adjusted for the age,
sex, International Staging System (ISS) stage (I vs. II; I vs.
III), cytogenetic risk defined by fluorescence in situ
hybridization (FISH) analysis [high, i.e. presence of
del(17p), t(4;14), t(14;16), vs. standard risk; missing vs.
standard risk], and autologous stem cell transplantation
(ASCT) (ASCT vs. non-ASCT; not applicable, i.e. patients
not candidate to ASCT, vs. non-ASCT). Subgroup analyses
were performed to determine the consistency of the over-
all effect in different subgroups using interaction terms for
the comparison between EMD versus non-EMD and each
of the co-variates included in the Cox model plus Revised
ISS stage (RISS) and type of therapies (IMID and PI). All
Hazard Ratios (HR) were estimated with their 95%CI and
two sided P-values. In order to evaluate the impact of dif-
ferent size and types of EMD, further subgroup analyses
were performed: EMD size ≤ 3 > 3 cm; EMD size ≤ 5 vs.
> 5 cm; PO or EMP. Data were analyzed as of December
2018 using and R (Version 3.1.1).
Results
Patients
A total of 2,332 patients were included in this analysis: 267
(11%) had EMD, while 2,065 (89%) had no EMD. Median age of
EMD patients was 68 years (IQ range 60-74), and 69 years (IQ
range 61-74) in patients without EMD. International Staging
System was I in 119 (45%) and 682 (33%), II in 85 (32%) and 782
(38%), and III in 38 (14%) and 509 (25%) patients with or without
EMD, respectively. Clinical trials were based on IMiD in 166
(62%) and 1,279 (62%) patients, on a PI in 66 (25%) and 464
(22%) patients, or both in 35 (13%) and 322 (16%) patients with
or without EMD, respectively. Patients' characteristics are summa-
rized in Table 2. Patients with EMD had PO in 243 (91%), and an
EMP in 12 (4%) cases, while the information was not available for
the other 12 (4%) patients. EMD localizations were single in 195
(73%), and multiple in 60 (22%) patients. Median EMD size was
4.2 cm (IQ range 3-7). EMD characteristics are summarized in
Table 3. No differences were observed in patients with EMD ≤ or
> 3 cm. EMD patients had a lower systemic tumor burden with
respect to patients without EMD, as shown by: plasma cell bone
marrow infiltration 30% (IQ range 15-50%) versus 50%  (IQ range
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30-70%), hemoglobin 12.0 gr/L (IQ range 10.5-13.6) versus 10.7
gr/L (IQ range 9.5-12.1), median creatinine clearance 75 mL/min
per 1.73 m2 (IQ range 48-98) versus 66 (IQ range 41-88), respective-
ly. EMD patients had ISS I stage in 45% of cases, compared to
33% in non-EMD patients (P<0.001).
Efficacy
Progression-free survival. The median follow up was 62
months (IQ range 34-75) in EMD, and 65 months (IQ range 40-77)
in non-EMD patients. Median PFS was 25.3 months (95%CI: 21.7-
28.7) and 25.2 months (95%CI: 24.2-27.0) in EMD and non-EMD
patients, respectively. Five-year PFS was 19% (95%CI: 15-25%)
and 22% (95%CI: 20-24%) (P=0.46) in EMD and non-EMD
patients, respectively (Online Supplementary Figure S1), and there
were no differences between EMP, PO, and non-EMD (Figure 1A).
In multivariate analysis the presence of EMD did not impact on
PFS (HR 1.15, 95%CI: 0.99-1.33; P=0.06), while other known
prognostic factors retained their significance: high risk versus stan-
dard cytogenetic (HR 1.35, 95%CI: 1.20-1.52; P<0.001), and ISS III
versus I (HR 1.74, 95%CI: 1.53-1.98; P<0.001) (Online
Supplementary Figure S2). Type of therapy had no impact on PFS:
IMiD-based therapy (HR 1.14, 95%CI: 0.96-1.35) and no IMiD
(HR 1.18, 95%CI: 0.87-1.59) (interaction P=0.86), PI-based therapy
(HR 1.33, 95%CI: 1.04-1.71) and no PI, (HR 1.04, 95%CI: 0.87-
1.25) (interaction P=0.12), and ASCT in eligible patients (HR 1.10,
95%CI: 0.81-1.50) and non-ASCT (HR 1.04, 95%CI: 0.73-1.47)
(interaction P=0.72). A landmark analysis from maintenance start
showed a median PFS of 23.4 months (95%CI: 19.1-30.1) and 23.5
months (95%CI: 21.8-25.7) (P=0.30) in EMD and non-EMD
patients, respectively. EMD size was not correlated with median
PFS: patients with EMD ≤3 cm 26.0 months (95%CI: 18.5-37.1),
patients with EMD >3 cm 23.7 months (95%CI: 18.8-28.2), and
patients without EMD 25.2 months (95%CI: 24.2-27.0) (Figure 2).
The same results were observed with the EMD size threshold at
5 cm (Online Supplementary Figure S3). Median PFS according to
EMD number was as follows: single EMD localization 26.1
months (95%CI: 22.5-30.1), multiple EMD localizations 19.4
months (95%CI: 14.9-33.1), and no EMD 25.2 months (95%CI:
24.2-27.0). Median PFS was not correlated with EMD site: PO 24.3
months (95%CI: 21.2-28.2), EMP 26.1 months (95%CI: 8.0-NR),
and no EMD 25.2 months (95%CI: 24.2-27.0), PO versus no EMD
(HR 1.14, 95%CI: 0.98-1.33; P=0.10), and EMP versus no EMD (HR
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Table 1. Source studies.
Trial                                  Code         Treatment                                    DrugsMaintenance  N. of         Years            Age       Outcome         Outcome  Pubblication
                                                                                                                                           Patients  enrollement population      PFS                  OS           year(s)
GIMEMA-MM-05-0528  2005-004714-32  4 PAD induction followed by 2      IMiD-PI        Yes            103         2005-2008           ≤75      Median PFS:         5yrs OS:      2010-2013
                                                                      Mel100 intensification followed                                                                                                        48 months              63%
                                                                      by 4 RP consolidation and R 
                                                                      maintenance                                                                                                                                                     
GIMEMA-MM-03-0529    NCT01063179    9 VMP induction or 9 VMPT           IMiD-PI    Random        511         2006-2009           ≥65      Median PFS:         5yrs OS:      2010-2014
                                                                      induction followed by 2 years                          for FDT                                                                     VMPT-VT:      VMPT-VT: 61%
                                                                      VT maintenance                                            or observation                                                              35 months          VMP:51%
                                                                                                                                                                                                                                              VMP:                                             
                                                                                                                                                                                                                                         25 months
RV-MM-PI-20930              NCT00551928    4 Rd induction, mobilization,              PI         Random        402         2007-2009           <65      Median PFS:         4yrs OS:           2014
                                                                      6 MPR or 2 Mel200 intensification        for maintenance                                                      MPR: 22 months    MPR: 65%
                                                                      followed by R maintenance                       or observation                                                        ASCT: 43 months   ASCT: 81%             
                                                                      until PD or observation                                             
RV-MM-EMN-44131         NCT01091831    4 Rd induction, mobilization,           IMiD           Yes             389         2009-2011           <65      Median PFS:         4yrs OS:           2015
                                                                      6 CPR or 2 Mel200 intensification                                                                                                CRD: 29 months    CRD: 73%
                                                                      followed by RP or R maintenance                                                                                               ASCT: 43 months   ASCT: 86%             
                                                                      until PD                                                      
EMN0132                           NCT01093196    9 Rd or MPR or CPR induction        IMiD           Yes             654         2009-2012           ≥65      Median PFS:         4yrs OS:           2016
                                                                      followed by RP or R maintenance                                                                                               MPR: 24 months    MPR: 65%
                                                                      until PD                                                                                                                                               CPR: 20 months    CPR: 68%              
                                                                                                                                                                                                                                      Rd: 21 months       Rd: 58%               
MMY206933                       NCT01190787    9 VP or CVP or VMP induction            PI              Yes             152         2010-2012           ≥65      Median PFS:         2yrs OS:           2016
                                                                      followed by V maintenance                                                                                                             VP: 14 months       VP: 60%
                                                                      until PD                                                                                                                                               VCP: 15 months     VCP: 70%              
                                                                                                                                                                                                                                    VMP: 17 months    VMP: 76%              
IST-CAR-50634                  NCT01346787    9 KCd induction followed                    PI              Yes              58          2011-2012           ≥65    2yrs PFS: 76%,   2yrs OS: 87%      2014
                                                                      by K maintenance until PD                                                                                                                                                                              
IST-CAR-56135                  NCT01857115    9 KCd induction followed                    PI              Yes              63          2013-2015           ≥65    2yrs PFS: 53%,  2yrs OS: 81%      2018
                                                                      by K maintenance until PD                                       
V: bortezomib; M: melphalan; P: prednisone; T: thalidomide; C: cyclophosphamide; K: carfilzomib; R: lenalidomide; d: dexamethasone; Mel200: high-dose melphalan; PAD: bortezomib-pegy-
lated liposomal doxorubicin -dexamethasone; PD: progression disease; IMiD: immunomodulatory drug; PI: proteasome inhibitor; PFS: progression-free survival; OS: overall survival; FDT:
fixed-duration therapy; yrs: years.
1.23, 95%CI: 0.64-2.37; P=0.54) (Figure 1A). Median PFS2 and 5-
year PFS2 were 43.2 months (95%CI: 37.0-52.4) and 38% (95%CI:
31-47%) in PO, 27.9 months (95%CI: 4.9-NR) and NR in EMP, and
46.4 months (95%CI: 44.1-48.9) and 40% (95%CI: 37-43%) in
non-EMD patients (Figure 3). 
Overall survival. Median OS was 63.5 months (95%CI: 48.2-
84.7) and 79.9 months (95%CI: 75.8-88.3; P=0.01) in EMD and
non-EMD patients, respectively. Five-year OS was 51% (95%CI:
45-58%) and 59% (95%CI: 57-61%) (P=0.01) in EMD and non-
EMD patients, respectively (Online Supplementary Figure S4), and
there was a significant difference between PO and non-EMD (HR
1.39, 95%CI: 1.13-1.70; P=0.001) (Figure 1B). In multivariate
analysis the presence of EMD was associated with a reduced OS
(HR 1.41, 95%CI: 1.16-1.71; P<0.001), in line with other known
prognostic factors: high risk versus standard cytogenetic (HR 1.68,
95%CI: 1.44-1.96; P<0.001), ISS III versus I (HR 2.36, 95%CI: 1.98-
2.82; P<0.001) (Online Supplementary Figure S5). Type of therapy
did not impact on OS: IMiD-based therapy (HR 1.38, 95%CI:
1.10-1.73) and no IMiD (HR 1.47, 95%CI: 1.01-2.13) (interaction
P=0.78), PI-based therapy (HR 1.43, 95%CI: 1.04-1.97) and no PI,
(HR 1.39, 95%CI: 1.09-1.76) (interaction P=0.87), and ASCT in eli-
gible patients (HR 1.45, 95%CI: 0.95-2.20) and non-ASCT (HR
1.40, 95%CI: 0.88-2.25) (interaction P=0.99). A landmark analysis
by maintenance start showed a median OS of 69.1 months
(95%CI: 64.6-NR) and 87.8 months (95%CI: 87.8-NR) (P=0.22) in
EMD and non-EMD patients, respectively. EMD size was not cor-
related with median OS: patients with EMD ≤3 cm 58.5 months
(95%CI: 38.4-NR), patients with EMD >3 cm 63.7 months
(95%CI: 48.2-NR), and patients without EMD 79.9 months
(95%CI: 75.8-88.3) (Figure 4). The same analysis was done with
the EMD size threshold at 5 cm (Online Supplementary Figure S6).
Median OS according to EMD number was as follows: single
EMD localization 70.1 months (95%CI: 50.4-NR), multiple EMD
localizations 45 months (95%CI:  38.2-NR), and no EMD 79.9
months (95%CI: 75.8-88.3), single EMD versus no EMD (HR 1.33,
95%CI: 1.07-1.67; P=0.01), and multiple EMD localizations versus
no EMD (HR 1.62, 95%CI: 1.11-2.38; P=0.01). Median OS was
not correlated with EMD site: PO 67.3 months (95%CI: 50.4-NR),
EMP 70.1 months (95%CI: 16.9-NR), and no EMD 79.9 months
(95%CI: 75.8-88.3), PO versus no EMD (HR 1.39, 95%CI: 1.13-
1.70; P=0.001), and EMP versus no EMD (HR 1.24, 95%CI: 0.55-
2.78; P=0.60) (Figure 1B). 
Discussion
To the best of our knowledge, this is the first meta-
analysis of MM clinical trials focusing on patients with
EMD so far reported. We included eight Fonesa Onlus and
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Figure 1. (A) Progression-free survival (PFS) and (B) overall survival (OS) according to extramedullary disease presence and type. EMD: extramedullary disease;
EMP: extramedullary plasmocytoma; PO: paraosseous plasmocytoma.
Figure 2. Progression-free survival (PFS) according to extramedullary disease features. (A) PFS according to extramedullary disease (EMD) presence and size. (B)
PFS according to single or multiple EMD localizations.
A
A B
B
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Table 2. Patients’ demographics and clinical characteristics.
Characteristic                           Patients with extra-medullary disease                   Control group                                                     P
                                                                        (N=267)                                             (N=2065)                                                          
Age
Median (IQR)-yr                                                    68 (60-74)                                                     69 (61-74)                                                                  0.21
Distribution – n. (%)                                                     
<65 yr                                                                       108 (40%)                                                     477 (38%)                                                                      
65 to 75                                                                     105 (39%)                                                     795 (38%)
≥ 75                                                                            54 (21%)                                                      493 (24%)                                                                      
ECOG                                                                                    
0                                                                                 107 (40%)                                                     847 (41%)                                                                  0.35
1                                                                                 103 (39%)                                                     862 (42%)
2                                                                                  39 (15%)                                                      235 (11%)
3                                                                                    1 (0%)                                                            7 (0%)                                                                         
ISS
I                                                                                  119 (45%)                                                     682 (33%)                                                                <0.001
II                                                                                 85 (32%)                                                      782 (38%)
III                                                                                38 (14%)                                                      509 (25%)
missing                                                                       25 (9%)                                                          92 (4%)                                                                        
R-ISS
I                                                                                   38 (14%)                                                      294 (14%)                                                                  0.62
II                                                                                125 (47%)                                                    1132 (55%)
III                                                                                 17 (6%)                                                         173 (8%)
missing                                                                      87 (33%)                                                      466 (23%)                                                                      
FISH – n. (%)                                                                                                                                                                                                                          0.72
Standard risk                                                          115 (43%)                                                    1082 (52%)
High risk*                                                                 51 (19%)                                                      446 (22%)
del(17p)                                                                     32                                                                   220 
t(4;14)                                                                         22                                                                   219 
t(14;16)                                                                        6                                                                     69 
Missing                                                                     101 (38%)                                                     537 (26%)                                                                      
LDH – IU/L                                                                                                                                                                                                                               0.30
≤450 201                                                                  201 (75%)                                                    1567 (76%)
>450 201                                                                   29 (11%)                                                       180 (9%)
missing                                                                      37 (14%)                                                      318 (15%)                                                                      
Bone marrow plasma cells, median (IQR)   30% (15% - 50%)                                        50% (30% - 70%)                                                          <0.001
Hemoglobin, median (IQR) – gr/L                 12.0 (10.5 – 13.6)                                          10.7 (9.5 – 12.1)                                                          <0.001
Creatinine clearance                                                                                                                                                                                                             0.01
Median (IQR) – mL/min per 1.73/m2                75 (48-98)                                                     66 (41-88)                                                                      
< 30 mL/min per 1.73/m2                                       45 (17%)                                                      359 (17%)
30 to 60 mL/min per 1.73/m2                                 49 (18%)                                                      544 (26%)
> 60 mL/min per 1.73/m2                                      172 (64%)                                                    1162 (56%)                                                                     
Therapy                                                                                                                                                                                                                                     0.48
IMiD-based                                                             166 (62%)                                                    1279 (62%)
PI-based                                                                    66 (25%)                                                      464 (22%)
IMiD + PI-based                                                     35 (13%)                                                      322 (16%)
Autologous stem cell transplantation                  155 (58%)                                                    1283 (62%)                                                                 0.17
Fixed-duration therapy                                            31 (12%)                                                      243 (12%)                                                                  1.00
Continuous treatment                                             128 (48%)                                                    1007 (49%)
No maintenance                                                        108 (40%)                                                     815 (39%)                                                                      
Imaging technique 
X-ray skeletal survey                                               0 (0 %)                                                        989 (42%)                                                                <0.001
CT-scan                                                                       0 (0 %)                                                       277 (13 %)
MRI                                                                           115 (43 %)                                                       0 (0 %)
Physical examination                                              21 (8 %)                                                          0 (0%)
Spiral CT                                                                    13 (5%)                                                           2 (0%)
Conventional CT                                                      96 (36%)                                                      675 (33%)
Unknown                                                                    22 (8%)                                                        122 (6 %)                                                                      
*More than one fluorescence in situ hybridization (FISH) abnormality may occur in the same patient. NS: not significant; NA:  not assessable; IQR:  interquartile range; IMiD:
immunomodulatory drug; PI:  proteasome inhibitor; CT:  computed tomography; MRI:  magnetic resonance imaging. ECOG: Eastern Cooperative Oncology Group.
Hovon Foundation clinical trials that enrolled 2,332 newly
diagnosed patients. In this population, we observed 267
(11%) patients with one or more EMD localizations,
including 243 PO, 12 EMP, and 12 cases that were not clas-
sified. Since none of the clinical trials considered in this
study had as primary end point the study of EMD, and a
proportion of them were started around ten years ago, the
most common imaging procedure performed at enroll-
ment as screening was X-ray skeletal survey, and, only in
case of a suspect of EMD, MRI or CT scan. X-ray skeletal
survey is clearly suboptimal in detecting extramedullary
asymptomatic disease. Nevertheless, the EMD incidence
we observed is in line with other case series (in the range
of 7-18%),1 suggesting that our patient population is quite
representative of the daily clinical practice. In any case, it
is expected that a wider use of more sensitive imaging
techniques, such as positron emission tomography (PET),
whole-body CT, and MRI will increase EMD detection.12,13
Interestingly, we observed that EMD patients had less dis-
ease burden, as shown by a more favorable ISS, lower
bone marrow plasma cell infiltrate, higher hemoglobin
levels, and a better renal function. This finding has been
observed also by others in the first line setting,2,14 and may
reflect a specific clinical picture, characterized by symp-
toms attributable to the EMD, rather than to larger disease
burden. The presence of EMD at diagnosis did not impair
the first line PFS, since EMD patients had a median PFS of
25.3 months, similar to the 25.2 months observed in
patients without EMD. This finding is quite remarkable,
since presence of EMD has long been recognized as an
unfavorable prognostic factor, both in case of PO and
EMP.4 Varettoni et al. described 76 EMD patients out of
1,003 MM patients at diagnosis, and with a treatment
based on conventional chemotherapy the PFS of EMD
was 18 versus the 30 months of patients without EMD
(P=0.03).2 Only EMD patients who received an ASCT had
a PFS  similar to that of patients without EMD. Likewise,
Wu et al. compared 75 EMD patients at diagnosis with 384
cases without EMD, and observed that EMD patients had
an inferior PFS compared to that of patients without EMD,
but this difference was overcome when EMD patients
received ASCT.14 Hence, the presence of EMD at diagnosis
has been incorporated as an adverse component of the
Durie and Salmon PLUS prognostic score.15 Since we did
not observe any significant difference in PFS between
EMD and non-EMD patients, it is reasonable to speculate
that the incorporation of new drugs in all the regimens
tested in the studies included in this meta-analysis was
able to overcome the unfavorable prognostic significance
of EMD. In this perspective, several case reports, as well
as a few trials, have shown that new drugs are effective in
MM patients with EMD. In particular, Landau et al. have
evaluated, in 42 high-risk MM at diagnosis including 14
patients with EMD, an induction with three cycles of
bortezomib, liposomal doxorubicin and dexamethasone,
followed by ASCT, with an acceptable median time-to-
progression of  39 months.16 In our meta-analysis, 166
EMD patients were treated with IMiD-based therapies
(lenalidomide in almost all cases) and have been compared
with 1,279 non-EMD patients who received the same
treatment. Quite surprisingly, also in this subset there was
no difference in PFS between the two groups, suggesting
that lenalidomide can be active also in this setting, as sug-
gested by very few case reports.17 This is in contrast with
the observation derived from studies involving thalido-
mide, the first-in-class IMiD, which resulted in having no
effect on EMD,18 and this may be accounted for by the
higher direct cytotoxic effect of lenalidomide respect to
thalidomide.19 Interestingly, in our study EMD patients
treated with IMiDs had the same PFS and OS as patients
treated with PI (Online Supplementary Figure S7).
Previous studies showed that increasing the therapy
intensity, i.e. intensifying the treatment with ASCT, over-
came the negative prognostic significance of EMD pres-
ence.20 This has been confirmed in a large European Bone
Marrow Transplantation registry study that considered
3,744 MM patients, including 353 with EMD, who
received ASCT at diagnosis.  This study has shown how
patients with a single EMD had a similar PFS to patients
without EMD.21 Since intensification seems to be the key
to EMD control, it is possible to speculate that new drugs
may offer a higher level of treatment intensity than con-
ventional drugs. In the pre-new drug era, this goal was
obtained only with ASCT.  In order to evaluate whether
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Figure 3. Progression-free survival (PFS2). EMD:
extramedullary disease; EMP: extramedullary
plasmocytoma; PO: paraosseous plasmocytoma.
the high efficacy of new drugs results in a more aggressive
relapse, we analyzed PFS2, and we observed that EMD
patients benefited from a similar disease control when
compared to patients without EMD (42.3 vs. 46.4 months,
respectively). This suggests that patients retain the benefit
beyond the first line. Interestingly, also maintenance
seems to have a similar efficacy in EMD and non-EMD
patients. Median OS of EMD patients was inferior when
compared with the control group (63.5 vs. 79.9 months,
respectively), and this is irrespective of the type of thera-
py. Since PFS2 is similar between the two groups, it is safe
to suggest that MM with EMD may acquire a more
aggressive behavior in later stages of the disease. 
Doubtless, the most sensitive technique for plasmacy-
toma identification is PET, which is able to upgrade
myeloma-related lesion identification in more than half of
patients when compared with X-ray skeletal survey.22
Unfortunately, in our study, PET was not used, since, at
the time the trials were performed, this was not a standard
technique. The recent IMAJEM trial, by the Intergroupe
Francophone du Myelome (IFM), has shown that spine
and pelvis MRI and PET are positive in 95% and 91% of
patients at diagnosis, respectively, and that PET has a
strong prognostic significance in terms of PFS and OS
when evaluated both after the induction phase, represent-
ed by three cycles of lenalidomide plus bortezomib plus
dexamethasone, and before maintenance start.23
Moreover, the IFM trial has shown that patients with
EMD, evaluated with PET at diagnosis, have an increased
risk of EMP relapse, progression or death (HR 3.4, 95%CI:
2.1-5.6; P<0.01). These data reinforce the concept that
EMP has a strong detrimental effect on survival, but a spe-
cific analysis on the clinical significance of PO disease was
not provided.  
Surprisingly, we did not find any significant correlation
between outcome and EMD size. A similar finding has
been reported in the setting of solitary EMD. Eighty-four
patients have been evaluated and no differences in terms
of outcome have been seen between patients with EMD
≤5 cm, >5 and ≤10 cm, and >10 cm.24 Probably, the pres-
ence of a EMD is detrimental for the relevant biological
features that are inherent in this variant of plasma cell neo-
plasm, rather than EMD size.25 Also the presence of single
or multiple EMD localizations was not prognostically sig-
nificant. Unfortunately, in our study, EMD was mainly
represented by PO disease, since many EMP were proba-
bly missed due to the imaging techniques used at the time
of trial design. Our observations are in contrast with the
study by Rasche et al.,26 who evaluated with diffusion-
weighted MRI 404 transplant-eligible patients and
showed that the presence of three or more large focal
lesions, defined as lesions with a product of the perpendi-
cular diameters >5 cm2, were strong independent adverse
prognostic factors. A possible explanation for this incon-
sistency can be attributed to the fact that Rasche et al. con-
sidered all types of focal lesions, including intraosseous
focal lesions, while in our study we only analyzed EMD.
Finally, we did not observe any significant correlation
between EMP and outcome, but this is probably due to
the limited number of cases observed in this study. 
In conclusion, the main limitation of out study  is  an
underestimation of EMD and, in particular, EMP inci-
dence, caused by the low resolution of  the imaging tech-
niques employed at screening. Thus, our findings can be
mainly referable to PO localizations, which are known to
be less aggressive than EMP;27 this limits the value of our
results. On the other hand, we performed the largest
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Figure 4. Overall survival (OS) according to extramedullary disease (EMD) features. (A) OS according to EMD presence and size. (B) OS according to single or multiple
EMD.
Table 3. Extramedullary disease characteristics. 
Characteristic                                                      N. patients=267
Size, median (IQR)-cm                                                         4.2 (3-7)
Para-skeletal                                                                           243 (91%)
Extramedullary plasmocytoma                                           12 (4.5%)
Not classifiable                                                                       12 (4.5%)
Single                                                                                        195 (73%)
Multiple                                                                                     60 (22%)
Not classifiable                                                                         12 (5%)
Involvement sites*§
Pelvis                                                                                             38
Skull                                                                                              10
Spine                                                                                            117
Thorax (excluding dorsal spine)                                           67
Long bones                                                                                  14
Not classifiable                                                                           34
*Sites of extramedullary disease (EMD) localizations were not available. §The sum of
the sites is greater than the total number of EMD patients, since one patient could
present with more than one localization. 
A B
analysis of EMD patients at diagnosis, with the strength of
using solid data derived from prospective trials. We con-
firmed that PI are effective towards EMD, and, for the first
time, we provide evidence that also lenalidomide is effec-
tive in this difficult setting. We hope that our and other
similar studies will draw attention to this unmet clinical
need with trials specifically designed for MM patients
with EMD. 
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